These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22736490)

  • 1. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
    Xie H; Jiang W; Jiang J; Wang Y; Kim R; Liu X; Liu X
    Cancer; 2013 Jan; 119(1):173-81. PubMed ID: 22736490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
    Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
    Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
    Zhang X; Jin FS; Zhang LG; Chen RX; Zhao JH; Wang YN; Wang EF; Jiang ZD
    Asian Pac J Cancer Prev; 2013; 14(7):4261-5. PubMed ID: 23991987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
    Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
    BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
    Han QL; Zhou YH; Lyu Y; Yan H; Dai GH
    J Clin Pharm Ther; 2018 Apr; 43(2):163-169. PubMed ID: 29214667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
    Akita H; Zheng Z; Takeda Y; Kim C; Kittaka N; Kobayashi S; Marubashi S; Takemasa I; Nagano H; Dono K; Nakamori S; Monden M; Mori M; Doki Y; Bepler G
    Oncogene; 2009 Aug; 28(32):2903-9. PubMed ID: 19543324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
    Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
    Br J Cancer; 2018 Apr; 118(8):1084-1088. PubMed ID: 29523831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
    Zhao LP; Xue C; Zhang JW; Hu ZH; Zhao YY; Zhang J; Huang Y; Zhao HY; Zhang L
    Chin J Cancer; 2012 Oct; 31(10):476-83. PubMed ID: 22692073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
    Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
    Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
    Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
    Br J Cancer; 2008 May; 98(10):1710-5. PubMed ID: 18414411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
    Xie H; Jiang W; Xiao SY; Liu X
    J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.